Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 52, Issue -, Pages 324-332Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.intimp.2017.09.009
Keywords
Inflammatory bowel diseases; Dextran sulfate sodium; Colitis; Maillard reaction products; Cytokines
Categories
Funding
- National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2017R1A2B4012182]
- Korea University [K1706241]
- School of Life Sciences and Biotechnology for BK21 PLUS, Korea University
- National Research Foundation of Korea [2017R1A2B4012182] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Inflammatory bowel diseases (IBDs) are chronic disorders that are characterized by intestinal epithelial inflammation and injury. Currently, the most employed therapies are antibiotics and anti-inflammatory drugs; however, the side effects limit long-term effectiveness. We evaluated the impact of glucose-lysine Maillard reaction products (Glc-Lys MRPs) on colitis, induced in rats by an administration of 5% dextran sulfate sodium (DSS) in drinking water. Glc-Lys MRPs ameliorate DSS-induced colitis, as determined by a decrease in disease index activity, colon weight/length ratio, nitric oxide levels in serum, recovery of body weight loss, colon length and serum lysozyme levels. Furthermore, Glc-Lys MRPs increase the glutathione content and the activity of glutathione peroxidase, superoxide dismutase and catalase, and inhibit lipid peroxidation and myeloperoxidase activity in colon tissues. In particular, Glc-Lys MRPs suppress the mRNA level of the inflammatory cytokines and nuclear factor-kappa B in colon tissues. This study suggests the potential of Glc-Lys MRPs in preventing or treating IBDs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available